An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients With Atopic Dermatitis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 31 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Apr 2017 Status changed from not yet recruiting to recruiting.
- 14 Feb 2017 New trial record